Back to Search Start Over

Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation

Authors :
Morisada, Tohru
Oike, Yuichi
Yamada, Yoshihiro
Urano, Takashi
Akao, Masaki
Kubota, Yoshiaki
Maekawa, Hiromitsu
Kimura, Yoshishige
Ohmura, Masako
Miyamoto, Takeshi
Nozawa, Shiro
Koh, Gou Young
Alitalo, Kari
Suda, Toshio
Source :
Blood; June 2005, Vol. 105 Issue: 12 p4649-4656, 8p
Publication Year :
2005

Abstract

Angiopoietin (Ang) signaling plays a role in angiogenesis and remodeling of blood vessels through the receptor tyrosine kinase Tie2, which is expressed on blood vessel endothelial cells (BECs). Recently it has been shown that Ang-2 is crucial for the formation of lymphatic vasculature and that defects in lymphangiogenesis seen in Ang-2 mutant mice are rescued by Ang-1. These findings suggest important roles for Ang signaling in the lymphatic vessel system; however, Ang function in lymphangiogenesis has not been characterized. In this study, we reveal that lymphatic vascular endothelial hyaluronan receptor 1-positive (LYVE-1+) lymphatic endothelial cells (LECs) express Tie2 in both embryonic and adult settings, indicating that Ang signaling occurs in lymphatic vessels. Therefore, we examined whether Ang-1 acts on in vivo lymphatic angiogenesis and in vitro growth of LECs. A chimeric form of Ang-1, cartilage oligomeric matrix protein (COMP)-Ang-1, promotes in vivo lymphatic angiogenesis in mouse cornea. Moreover, we found that COMP-Ang-1 stimulates in vitro colony formation of LECs. These Ang-1-induced in vivo and in vitro effects on LECs were suppressed by soluble Tie2-Fc fusion protein, which acts as an inhibitor by sequestering Ang-1. On the basis of these observations, we propose that Ang signaling regulates lymphatic vessel formation through Tie2. (Blood. 2005;105:4649-4656)

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
105
Issue :
12
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs57170557
Full Text :
https://doi.org/10.1182/blood-2004-08-3382